5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Anuh Pharma Ltd.

•
anuhpharma.comBSE: 506260NSE: ANUHPHR
Market Cap₹ 948 Cr.
Current Price
High / Low₹ 100 / 67
Stock P/E21.5
Book Value₹ 36
Price to Book1.91
Dividend Yield1.59 %
ROCE16.0 %
ROE12.1 %
Face Value₹ 5

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 21.8%
  • Latest quarter profit grew 37.7% YoY, showing strong momentum
  • Company has been maintaining a healthy dividend payout of 36.6%
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • Operating cash flow has been negative in recent years
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.32x)
  • Valuation is stretched - P/E of 21.5 is well above its own 5-year median (10.2)
  • Company has delivered a poor profit growth of 7.6% over past five years
  • Operating margins have contracted to 7.4% from 10.9%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.ANUHPHR94.6221.47948.321.59114.251276.511938.10939.3116.028.40
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1611501721641381661601981861861972021,938
1481321481451271491451791761741801821,800
Operating Profit141824191117151910121720139
OPM %8.65%12.01%13.94%11.73%7.66%10.17%9.27%9.42%5.52%6.39%8.52%9.84%7.15%
32434311314-131
Interest0000000000000
Depreciation22222223333324
Profit before Tax151825201218131711101816169
Tax %23.75%22.60%24.46%22.11%22.49%17.32%22.00%27.89%24.20%23.29%24.57%24.74%32.51%
Net Profit1214191510151012881312114
2.352.763.813.061.901.501.031.241.660.761.341.171.14

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
206238321307432487527647662772779
183220291284387439476571600714717
Operating Profit2318302345475276625762
OPM %11.00%7.70%9.34%7.57%10.45%9.75%9.82%11.71%9.30%7.44%8.01%
8754115612997
Interest10112211110
Depreciation2227151210991111
Profit before Tax2823321939394778615460
Tax %27.32%29.49%27.89%25.32%26.24%21.88%23.78%23.31%22.38%24.30%26.63%
Net Profit2017231428313660474144
EPS0.000.000.000.005.676.107.2211.989.454.10—
Dividend Payout %31.24%41.73%29.49%48.17%26.43%28.70%27.70%20.86%15.87%36.63%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
12%
3 Years:
14%

COMPOUNDED PROFIT GROWTH

10 Years:
5%
5 Years:
8%
3 Years:
4%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
9%

RETURN ON EQUITY

10 Years:
15%
5 Years:
16%
3 Years:
17%
Last Year:
12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2025

Jul 15

1:1

Audited Results & Final Dividend & Bonus issue

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital13131313252525252550
128137152150166189216266301302
0244514412110
Trade Payables425259105120122153141157188
541115889111114
Total Liabilities187208239326333347404445505554
17172184716153495857
Capital Work in Progress06340000000
706639803143919710684
303243618180737574148
0000000190216239
Cash & Bank68113201678208
63799199128147181253018
Total Assets187208239326333347404445505554

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
3491754-938671337-3
Cash from Investing-2023-7752-8-431-2018
Cash from Financing-4-5-722-33-19-12-9-5-26
2-13-502-2512-11

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
69.9269.9269.9269.9269.9271.8271.8271.8071.80
0.030.020.020.040.040.000.000.050.01
DIIs0.000.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.000.00
30.0530.0630.0630.0530.0428.1828.1828.1628.19

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-19
Investor Presentation

2026-08-19 - Anuh Pharma Limited has informed the Exchange about Investor Presentation

2026-08-14
Change in Management

2026-08-14 - Anuh Pharma Limited has informed the Exchange about change in Management

2026-08-14
Appointment

2026-08-14 - Anuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.

2026-08-14
General Updates

2026-08-14 - Anuh Pharma Limited has informed the Exchange about General Updates under Regulation 30.

2026-08-14
Shareholders meeting

2026-08-14 - Anuh Pharma Limited has submitted the Exchange a copy Voting Results and Scrutinizers report of Annual General Meeting held on August 12, 2026.

2026-08-12
Shareholders meeting

2026-08-12 - Anuh Pharma Limited has informed the Exchange regarding Proceedings of 66th Annual General Meeting held on August 12, 2026

2026-08-09
Copy of Newspaper Publication

2026-08-09 - Anuh Pharma Limited has informed the Exchange about Copy of Newspaper Publication of the Unaudited financial results for the Quarter ended 30th June, 2026, published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi Language on 09th June, 2026.

2026-08-07
Updates

2026-08-07 - Anuh Pharma Limited has informed the Exchange regarding 'Adoption of Revised Policy of Related Party Transactions.'.

2026-08-07
Updates

2026-08-07 - Anuh Pharma Limited has informed the Exchange regarding 'Request received for Withdrawal of application for reclassification of shareholding from Promoter & Promoter Group to Public Category'.

News

Recent coverage and analyst commentary for ANUHPHR

Loading news…

🤖

AI Stock Analyst

Anuh Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login